Industry Updates for the Psychedelics World

Psychedelics News

Industry

30 Dec 2022

2022 End-of-Year Review: MindMed

Continuing our series of 2022 end-of-year reviews, we take a look at MindMed’s last 12 months....

By Jason Najum

Industry

28 Dec 2022

2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine

James Hallifax takes a look at 3 psychedelic Clinical Trials Pushing Boundaries of Psychedelic Medicine in 2022...

By James Hallifax

Industry

27 Dec 2022

2022 End of Year Review: Small Pharma

Continuing our end-of-year review, we’ll take a moment to update DMT company Small Pharma’s last 12 months....

By Microdose NewsDesk

Industry

23 Dec 2022

atai Life Sciences Announces Results of Phase 1 Trial for KUR-101

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

22 Dec 2022

Small Pharma Completes Phase IIa Trial and Secures New IP

DMT-development firm Small Pharma has moved its lead candidate drug further through the clinical trial process with the completion of its Phase 2a trial....

By Microdose NewsDesk

Industry

21 Dec 2022

2022 End of Year Review: Cybin

The end of the year is a convenient time to look back on the psychedelic medicine space and take stock on the progress of both the industry and individual companies....

By Microdose NewsDesk

Industry

20 Dec 2022

Top 5 Psychedelic Milestones of 2022

2022 was a big year for psychedelic medicine industry, we take a look at the top 5 psychedelic milestones for 2022...

By James Hallifax

Industry

19 Dec 2022

Atai Initiates Phase 2b Trial of RL-007 for Schizophrenia

Atai's new phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)....

By Microdose NewsDesk

Industry

15 Dec 2022

PharmaTher Receives FDA Orphan Drug Designation for Ketamine

The U.S. Food and Drug Administration (FDA) has granted PharmaTher orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result